| HOME >> BIOLOGY >> TECHNOLOGY |
HORSHAM, Pa. and KENILWORTH, N.J., Nov. 6 /PRNewswire/ -- Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now been treated with REMICADE(R) (infliximab), the leading anti-tumor necrosis factor (TNF)-alpha therapy worldwide. In fact, REMICADE has been used to treat more patients worldwide than all other anti-TNF-alpha agents combined. REMICADE was the first anti-TNF-alpha treatment approved by the U.S. Food and Drug Administration (FDA), when it was indicated for the treatment of acute moderate to severe Crohn's disease in 1998. The indication for Crohn's disease was quickly followed by additional indications, such as rheumatoid arthritis.
"Rheumatoid arthritis derailed my life," said Ellen Shmueli, RA patient. "Simple tasks like lifting my child or holding a pen were nearly impossible. It's hard to put into words what REMICADE has meant to me."
Through a long line of firsts in the biotechnology industry, the history of REMICADE includes 15 FDA indications spanning across inflammatory diseases that include Crohn's disease (adult and pediatric), ulcerative colitis, rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis and psoriasis.
"This significant milestone was achieved as a result of nearly three decades of expanding and improving access for people living with life-altering inflammatory diseases," said Neal Fowler, President, Centocor, Inc. "In partnership with Centocor R&D, we will continue our pledge of bringing the promise of biomedicine to physicians and patients through continued research and development, REMICADE and our promising pipeline portfolio."
REMICADE has been studied in more than 37 clinical trials, evaluating its use in a wide variety of diseases of the immune system and is approved for use in 88 countries.
"Having been a part of its initial approval in 1998, I have personally
witnessed how REMICAD
'/>"/>
| SOURCE Centocor, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
2. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
3. Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
7. Genmab Announces 2007 First Half Year Results
8. Pharsight Achieves First License Sale for Public-Source Database
9. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. China Medical Technologies Reports First Quarter Financial Results
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |